A director at Bumrungrad Hospital Public Company Limited sold 95,000 shares at 206.000THB and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
BH reported a net profit of Bt1.96b in 3Q24 (+0.0% yoy, +1.2% qoq) which disappointed the market due to lower-than-expected revenue. Revenue from both Thai and foreign patients declined yoy. We believe that in the long term, BH still has strong fundamentals as construction of its new hospital in Phuket has already started and capacity expansion at the main campus is underway. Maintain BUY. Target price: Bt303.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt33.00/Target: Bt45.00) 3Q24: Earnings hurt by weaker GIM and inventory loss Bangchak Sriracha (BSRC TB/BUY/Bt7.10/Target: Bt9.00) 3Q24: Results better than expected. Berli Jucker (BJC TB/BUY/Bt23.40/Target: Bt28.00) 3Q24: Earnings in line; expect 4Q24 EBIT to continue to improve yoy. Bumrungrad Hospital (BH TB/BUY/Bt262.00/Target: Bt303.00) 3Q24: Di...
GREATER CHINA Economics Trade Surprising beat on exports. Sector Automobile Weekly: Trump’s tariff to reshape China automobile supply chain. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao Glass and Desay SV. Results Galaxy Entertainment Group (27 HK/BUY/HK$36.35/Target: HK$46.00) 3Q24: EBITDA decline due to higher reinvestmen...
BH’s operations have surpassed pre-COVID-19 levels with ease, and continue to grow. Going forward, growth will be bolstered by capacity expansion at the main campus and the new hospital in Phuket as well as the strong arrival of Middle East patients. We are positive that BH could see a strong performance in 3Q24, driven by the rainy season in Thailand and Middle Eastern patients having finished their Ramadan fasting period. Upgrade to BUY. Target price: Bt303.00.
KEY HIGHLIGHTS Strategy China’s Stimulus Boosts Sentiment For China-Related Companies F&B, agriculture and petrochem are the top beneficiaries but we see better upside and opportunities for hotel and tourism. Update Bumrungrad Hospital (BH TB/BUY/Bt270.00/Target: Bt303.00) The strongest quarter in 2024 is ahead of us. Upgrade to BUY.
INDONESIA Sector Telecommunications: Telcos’ mobile data revenue could grow 7% yoy; maintain OVERWEIGHT. MALAYSIA Strategy China Economic Recovery Beneficiaries: Hopes of China’s major fiscal stimulus and economic recovery may provide further trading opportunities for Malaysian beneficiary stocks. Sector Banking: Loan growth slowed down to 6.0% from 6.4% in Aug 24. The absence of strong earnings catalyst has prompted us to maintain MARKET WEIGHT. Results Yinson (YNS MK/BUY/RM2.68/Target: RM3.90...
GREATER CHINA Strategy Small-Mid Cap Monthly Reiterate BUY on Plover Bay Technologies. Sector Automobile Weekly: Sales of top 12 EV brands up 38% wow last week, in line. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL and Tuopu. Top SELL: XPeng. INDONESIA Update Sarana Menara Nusantara (TOWR IJ/BUY/Rp745/Target: Rp890) Number of towers to jump 10% on a...
GREATER CHINA Economics Inflation: Disinflation continues but a turnaround likely in near future. Strategy Small-Mid Cap Biweekly: Eyeing stimulus for home furnishing consumption; beneficiaries are ZBOM Home Collection Co and Man Wah Holdings. Sector Commodities: Weekly: Economic data surprises on the downside; production restrictions to ease inventory pressure. INDONESIA Strategy Feedback On Inflation-linked Investment Opportunities: Our top picks: Banking − BBNI, BBTN, BTPS; consumer − MYOR, ...
We expect BH’s 2Q23 earnings to soften qoq mainly due to seasonality and rising staff costs, despite limited downside following the rebound in patient numbers from the Middle East in May-Jun 23. We are optimistic in 3Q23 as 3Q is the high season, but remain cautious due to limited incremental bed capacity, intense competition and lower oil prices. Maintain HOLD. Target price: Bt235.00.
We expect BH’s growth in the rest of 2023 to falter as the hospital is currently operating close to full capacity, with a possibility of a slight slowdown in 2Q23. BH has announced plans to construct Bumrungrad International Hospital Phuket as a new campus, but the details are not fully disclosed and a few years are required for the new projects to materialise. Maintain HOLD. Target price: Bt235.00.
KEY HIGHLIGHTS Sector Media 1Q23 results preview: Cloudy outlook has not faded. Results Thai Union Group (TU TB/BUY/Bt13.60/Target: Bt17.00) 1Q23: Lower than expected; 2Q23 earnings expected to improve qoq. Update Bumrungrad Hospital (BH TB/HOLD/Bt243.00/Target: Bt235.00) Decelerating growth as the recovery has already beaten the pre-COVID-19 level. CP ALL (CPALL TB/BUY/Bt64.25/Target: Bt78.00) We expect the Cambodian market to be CPALL’s long-term upside driver. PTT (PTT TB/BUY/Bt30.50/Tar...
GREATER CHINA Update Xiaomi Corp (1810 HK/HOLD/HK$11.16/Target: HK$11.10): 1Q23 results preview: Margin expansion to more than offset decline in shipments. INDONESIA Results Indocement Tunggal Prakarsa (INTP IJ/BUY/Rp10,000/Target: Rp13,500): 1Q23: NPAT in line with expectations; improvement in margins. MALAYSIA Results Westports Holdings (WPRTS MK/HOLD/RM3.48/Target: RM3.80): 1Q23: Core profit was in line, owing to above-peers container volume growth. Cost upside was well contained. SINGAPOR...
BH posted a slight earnings beat in 1Q23 from robust patient demand since 2022. Although margins continue to be strong, a scenario of another consecutive positive qoq earnings growth remains uncertain, which can limit the upside given demanding valuation. Maintain HOLD. Target price: Bt235.00.
KEY HIGHLIGHTS Sector Hotel 1Q23 earnings preview: Hotels in rural Thailand have the most outstanding performance. Property 1Q23 results preview: Earnings to decrease yoy and qoq. Results Bumrungrad Hospital (BH TB/HOLD/Bt241.00/Target: Bt235.00) 1Q23: Marginal earnings beat on robust revenue.
GREATER CHINA Results BYD Company (1211 HK/BUY/HK$236.00/Target: HK$590.00): 1Q23: Results miss on forex loss. Maintain BUY. Target price: HK$590.00. Xinjiang Goldwind (2208 HK/HOLD/HK$6.56/Target: HK$7.40): 1Q23: Below expectations; earnings boosted by wind farm disposal. Update KE Holdings Inc (2423 HK/BUY/HK$40.90/Target: HK$62.00): 1Q23 results preview: Resilient recovery at home brokerage business. INDONESIA Results Unilever Indonesia (UNVR IJ/BUY/Rp4,400/Target: Rp5,700): 1Q23: Recovery i...
GREATER CHINA Results China Construction Bank (939 HK/BUY/HK$5.07/Target: HK$6.06): 2022: Results in line; expect NIM compression to continue in 2023. China Mengniu Dairy (2319 HK/BUY/HK$32.60/Target: HK$39.30): 2022: Results below expectations; upbeat on future margin expansion. Ganfeng Lithium (1772 HK/SELL/HK$49.45/Target: HK$35.00): 4Q22: Earnings missed our estimates; maintain SELL. Guangzhou Automobile Group (2238 HK/SELL/HK$4.99/Target: HK$4.00): 4Q22: Results grossly missed estimates. Ma...
We expect BH to post a small qoq drop in 1Q23 net profit, but it is still robust compared to pre-COVID-19 levels due to the persistent demand from international patients. Although BH is expected to have a good year in 2023, the market is believed to have factored in the positive expectations while a small setback in patient volume is likely in 2Q23. Maintain HOLD. Target price: Bt229.00.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.